Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 4
1992 6
1993 7
1994 3
1995 4
1996 6
1997 6
1998 3
1999 5
2000 15
2001 17
2002 24
2003 18
2004 27
2005 35
2006 29
2007 41
2008 53
2009 64
2010 64
2011 62
2012 63
2013 61
2014 84
2015 104
2016 85
2017 98
2018 118
2019 147
2020 144
2021 179
2022 204
2023 186
2024 215
2025 272
2026 162

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,370 results

Results by year

Filters applied: . Clear all
Page 1
The epithelial barrier theory and its associated diseases.
Sun N, Ogulur I, Mitamura Y, Yazici D, Pat Y, Bu X, Li M, Zhu X, Babayev H, Ardicli S, Ardicli O, D'Avino P, Kiykim A, Sokolowska M, van de Veen W, Weidmann L, Akdis D, Ozdemir BG, Brüggen MC, Biedermann L, Straumann A, Kreienbühl A, Guttman-Yassky E, Santos AF, Del Giacco S, Traidl-Hoffmann C, Jackson DJ, Wang DY, Lauerma A, Breiteneder H, Zhang L, O'Mahony L, Pfaar O, O'Hehir R, Eiwegger T, Fokkens WJ, Cabanillas B, Ozdemir C, Kistler W, Bayik M, Nadeau KC, Torres MJ, Akdis M, Jutel M, Agache I, Akdis CA. Sun N, et al. Among authors: bu x. Allergy. 2024 Dec;79(12):3192-3237. doi: 10.1111/all.16318. Epub 2024 Oct 7. Allergy. 2024. PMID: 39370939 Free PMC article. Review.
Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts.
Wang J, Huang S, Lan G, Lai YJ, Wang QH, Chen Y, Xiao ZS, Chen X, Bu XL, Liu YH, Zeng F, Zhang L, Li A, Cai Y, Sun P, He Z, Doré V, Fripp J, Bourgeat P, Chen Q, Yu JT, Tang Y, Zetterberg H, Masters CL, Guo T, Wang YJ; Translational Biomarker Research of AgIng and Neurodegeneration (TBRAIN). Wang J, et al. Among authors: bu xl. Alzheimers Dement. 2025 Mar;21(3):e70038. doi: 10.1002/alz.70038. Alzheimers Dement. 2025. PMID: 40156286 Free PMC article.
The Evolution, Immunopathogenesis and Biomarkers of Type 2 Inflammation in Common Allergic Disorders.
Gao YD, Wang ZJ, Ogulur I, Li SJ, Yazici D, Li XH, Pat Y, Zheng Y, Babayev H, Zeyneloglu C, Li YC, Ardicli S, Tian WQ, Ardicli O, Chen SW, Bu XT, Lu G, Chang LH, He Y, Guttman-Yassky E, Cabanillas B, Ozdemir C, Kiykim A, Shamji M, Nadeau K, Torres MJ, Akdis M, Akdis CA. Gao YD, et al. Among authors: bu xt. Allergy. 2025 Jul;80(7):1848-1877. doi: 10.1111/all.16620. Epub 2025 Jun 30. Allergy. 2025. PMID: 40586319 Review.
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study.
Baraliakos X, van der Heijde D, Sieper J, Inman RD, Kameda H, Maksymowych WP, Lagunes-Galindo I, Bu X, Wung P, Kato K, Shmagel A, Deodhar A. Baraliakos X, et al. Among authors: bu x. Arthritis Res Ther. 2024 Nov 12;26(1):197. doi: 10.1186/s13075-024-03412-8. Arthritis Res Ther. 2024. PMID: 39533349 Free PMC article. Clinical Trial.
Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.
van Vollenhoven R, Strand V, Takeuchi T, Chávez N, Walter PM, Singhal A, Swierkot J, Khan N, Bu X, Li Y, Penn SK, Camp HS, Aelion J. van Vollenhoven R, et al. Among authors: bu x. Arthritis Res Ther. 2024 Jul 29;26(1):143. doi: 10.1186/s13075-024-03358-x. Arthritis Res Ther. 2024. PMID: 39075620 Free PMC article. Clinical Trial.
Targeted destruction of VISTA boosts anti-tumor immunotherapy.
Chen L, Bu X, Sun Y, Huang D, Chen Y, Hou T, Hu X, Wang J, Yan P, Qi Y, Jiang W, Xiong Y, Liu J, Gao Y, Huan M, Wang B, Liu Q, Dai X, Dang F, Asara JM, Fujimoto M, Inuzuka H, Jin J, Zhang J, Freeman GJ, Wei W. Chen L, et al. Among authors: bu x. Cell Res. 2025 Dec;35(12):987-1002. doi: 10.1038/s41422-025-01194-5. Epub 2025 Nov 13. Cell Res. 2025. PMID: 41225154 Free PMC article.
Destruction of VISTA by TRIM25 ablation in T cells potentiates cancer immunotherapy.
Sun Y, Zhang Z, Li H, Bu X, Chen L, Wang X, Fan L, Chen B, Kong L, Dai P, Song W, Xiao X, Shi J, Xiang B, He C, Yao Y, Xiong W, Yu H, Jiang C, Qian Q, Liu H, Tian S, Qing G, Yang Z, Wei W, Freeman GJ, Zhu H, Zhang J. Sun Y, et al. Among authors: bu x. Cell Res. 2025 Dec;35(12):1003-1020. doi: 10.1038/s41422-025-01186-5. Epub 2025 Nov 13. Cell Res. 2025. PMID: 41225152
2,370 results